Towards safer risperidone prescribing in Alzheimer's disease.

Suzanne J ReevesJulie BertrandHiroyuki UchidaKazunari YoshidaYohei OtaniMikail OzerKathy Y LiuElvira BramonRobert BiesBruce G PollockRobert Howard

Published in: The British journal of psychiatry : the journal of mental science (2020)

Our findings argue for age- and MMSE-related dose adjustments and suggest that a single measure of the concentration-to-dose ratio could be used to identify those with slower drug clearance.

Keyphrases

primary care
adverse drug
cognitive decline
drug induced